IMUNON’s IMNN-001 Shows 14.7-Month OS Gain, Phase 3 Enrollment Ahead
IMUNON’s IMNN-001 Phase 2 OVATION 2 trial showed a median overall survival gain of 14.7 months (45.1 vs. 30.4) over standard chemotherapy, rising to 24.2 months (65.6 vs. 41.4) with PARP inhibitor maintenance. Enrollment in the pivotal Phase 3 OVATION 3 study remains ahead of plan on strong investigator interest.
1. Phase 2 OVATION 2 Study Results
Final data from the Phase 2 OVATION 2 trial in 112 women with newly diagnosed advanced ovarian cancer demonstrated a median overall survival improvement of 14.7 months (45.1 vs. 30.4) in the IMNN-001 arm versus standard of care, with a 24.2-month gain (65.6 vs. 41.4) when combined with PARP inhibitor maintenance.
2. Phase 3 OVATION 3 Enrollment
Enrollment in the Phase 3 OVATION 3 pivotal trial continues to outpace forecasts, reflecting robust engagement from principal investigators and the medical community as the study advances toward its interim overall survival analysis.
3. Safety and Translational Data
IMNN-001 maintained a favorable safety and tolerability profile, with translational findings showing activation of innate and adaptive immune cells and conversion of the tumor microenvironment from ‘cold’ to ‘hot,’ supporting its mechanism of action.
4. Financial Results and Outlook
IMUNON reported its 2025 year-end financial results and held a conference call to discuss these clinical milestones, outlining a clear regulatory pathway and an adaptive, event-driven Phase 3 design aimed at securing full approval based on survival outcomes.